{
    "relation": [
        [
            "",
            "Placebo",
            "Dasatinib"
        ],
        [
            "Description",
            "Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily",
            "Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily"
        ]
    ],
    "pageTitle": "Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00744497?sect=Xec015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987127.36/warc/CC-MAIN-20150728002307-00131-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 864462040,
    "recordOffset": 864446420,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups A total of 1930 participants were enrolled, and 1522 were randomized to a treatment group; 1518 received at least 1 dose of dasatinib (761) or placebo (757). Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Placebo Drug: Dasatinib Drug: Docetaxel Drug: Prednisone Interventions: Prostatic Neoplasms Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Placebo \u00a0 \u00a0 Dasatinib \u00a0 STARTED \u00a0 \u00a0 760 [1] \u00a0 762 [1] Received Treatment \u00a0 \u00a0 757 \u00a0 \u00a0 761 \u00a0 COMPLETED \u00a0 \u00a0 43 [2] \u00a0 39 [2] NOT COMPLETED \u00a0 \u00a0 717 \u00a0 \u00a0 723 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 21 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 17 \u00a0 Death \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 11 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 7",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}